Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data
Big Pharma is racing to carve out an early lead in TIGIT, a potential third immune checkpoint that could offer billions in sales. Roche has led the way there, but small biotech Arcus is advancing its own candidate alongside some big-name partners of their own — and after a mid-stage check-in, the company is going positive with very little on hand to show.
In a cryptic update, Arcus said its anti-TIGIT drug domvanalimab showed “encouraging clinical activity” in a Phase II open-label study testing the drug alongside an investigational PD-1 therapy, and in a triplet therapy including those two drugs and dual adenosine A2a/A2b receptor antagonist etrumadenant, in metastatic non-small cell lung cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.